Sermo built a doctors’ lounge. Then it found buyers for the conversation.

Doctors have questions they would rather ask another doctor. A difficult case. A drug that looks better on paper than it behaves in practice. A career decision that deserves a frank answer. Sermo gives those conversations a room of their own. It also gives healthcare companies a way to commission research from the people inside it.

That arrangement makes Sermo more interesting than another professional feed. The member-facing offer is free: compare notes, read physician drug reviews, discuss cases and earn money from qualifying surveys. The commercial offer is research and engagement with a verified healthcare audience. One group brings experience; another has questions worth paying to answer.

The company’s About page reports reach across more than 1.3 million healthcare professionals in 150 countries. Its physician community sits alongside separate spaces for other professions, including advanced practice providers and pharmacists. Those distinctions matter. A large collection of health professionals is useful, but the right professional for a particular question is what the customer needs.

A doctors’ network needed a passport

Sermo’s original company was founded in 2005 by physician Daniel Palestrant; the website launched in 2006. Its early premise grew from concern about how doctors shared observations of adverse drug effects after the Vioxx controversy. A forum could let clinicians compare what they were seeing before those observations worked their way through slower channels.

The idea attracted attention and venture capital. By July 2012, Sermo had 130,000 physician members and clients that included eight of the ten largest pharmaceutical companies, according to its acquisition announcement. Yet contemporary reporting described membership growth slowing after the early rush. Busy doctors did not automatically become habitual social network users.

The commercial constraint was more specific. Then-CEO Tim Davenport said “clients asked for global reach and more key specialists.” WorldOne, a healthcare research company led by Peter Kirk, acquired Sermo that month. It brought an international respondent network; Sermo brought a community and experience getting physicians to interact online.

“clients asked for global reach and more key specialists”

Tim Davenport · Sermo CEO at the time of the 2012 acquisition

This was a practical change of scale and capabilities. The question had become how to deliver the audiences customers wanted, beyond the original U.S. network. More than $40 million in venture money had gone into Sermo before the sale, contemporary reporting said. The acquisition price was undisclosed, so the transaction cannot be treated as a documented investor windfall.

Abry Partners backed a recapitalization in February 2019. Sermo said the investment would support a new member experience and more automation for research customers. By then, the ambition was to connect its service operation and software more closely: help doctors participate, and make the resulting research easier for clients to commission and use.

The drug review has an insurance problem

Drug Ratings, launched in May 2017, captures the company’s appeal in a compact form. Physicians rate treatments on efficacy, safety, tolerability, accessibility and adherence. The last two categories are particularly revealing. A medicine’s usefulness in everyday practice depends partly on whether a patient can obtain it and keep taking it.

Sermo reported reaching one million physician drug ratings in 2021. By October 2025, its support guidance confirmed that the ratings were publicly viewable by other healthcare professionals and consumers. Authorship remained restricted to verified, licensed physicians. Opening the reading room did not mean handing everyone a pen.

The ratings also supply a business product: a way to study perceptions of a brand and its alternatives. In an October 2025 GLP-1 report, Sermo combined ratings from more than 1,100 physicians with survey responses from over 300 active prescribers. The angle was the gap between treatment promise and the access hurdles encountered in practice.

These are reports of experience. They do not establish comparative efficacy the way a controlled trial would. For a clinician, their value is context and questions to investigate. For a company, they can reveal friction that an otherwise polished product presentation overlooks. A star score needs to be read with its contributors and circumstances in mind.

Five days, 72 completions, one business question

To see what customers actually buy, look at a 2021 Sermo case study. An unnamed pharmaceutical manufacturer wanted input on its atopic dermatitis product roadmap and value proposition. Sermo built a moderated online advisory community involving pharmacists and dermatology nurses in Asia-Pacific and Europe, plus European nurse practitioners.

The assignment had five daily question sets, an expected two to three hours of participation and moderator interaction. Sermo reported 72 completions over five days. Its team selected participants for fit, developed a discussion guide, moderated the exchange and turned the responses into a report. The useful unit was a finished research project.

That example shows why software is only part of the offering. Research design and recruitment determine whether answers address the question. Moderation determines whether a discussion gets past first impressions. Analysis determines whether a team can do anything with the responses. Sermo sells that work alongside access to its network.

Its broader research menu includes interviews, focus groups, quantitative studies, rapid RealTime surveys and reporting support. Pharmaceutical, biotech and medical device companies are buyers, as are research organizations and consultants. Sermo’s historical customer list includes Pfizer, Novartis, McKinsey and ZS. Each may need a different slice of clinical experience.

The person prescribing is only part of the market

In February 2023, Sermo announced acquisitions of Payer Access and Charter Oak, expanding its reach into payer decision-making and oncology research. The logic follows the drug ratings’ accessibility category: understanding prescribing requires attention to who influences reimbursement and access, too. A product can encounter resistance well beyond the consulting room.

Sermo occupies an overlap between professional networking and healthcare research. Doximity offers a competing destination for clinician attention, with professional communication and workflow tools. M3 Global Research is an alternative for healthcare fieldwork and respondent recruitment. Sermo combines the repeat visits of a community with the targeted questioning of a research panel.

That combination is useful when a customer needs both a defined audience and context about its concerns. It is less useful when the task requires evidence outside the panel’s experience or a representative estimate the study design cannot support. Network size alone settles neither question. A buyer still needs the right sample, a clear brief and sensible interpretation.

Known at the door, anonymous in the room

Sermo allows members to participate anonymously with peers while verifying their professional identity. Its published quality process includes medical credential checks, identity validation and duplicate detection. It also describes more than 30 ongoing quality checks, automated survey controls and manual data review. The alias and the credential serve different purposes.

For members, the appeal is room for candor without making every comment part of a public professional profile. For customers, verification supports confidence that respondents have the claimed expertise. Those two expectations meet inside the same product. Sermo has to maintain both if it wants useful participation to continue.

The incentives are explicit. Membership is free; qualifying research participation earns honoraria. Sermo’s current earnings page says it paid HCPs more than $25 million in the preceding year, without fixing that claim to a calendar year on the page. An individual’s earnings depend on eligibility and available studies. A survey invitation is an opportunity, not a salary.

The commercial arrangement has changed over time. A 2010 Sermo announcement described the service as advertising-free. In October 2025, it launched Engagement Manager, allowing pharmaceutical and health-adjacent brands to run campaigns themselves. Its business homepage says customers pay for the engagements they receive and can monitor performance in real time.

Research participation and promotional engagement therefore need to remain intelligible to the people using the network. Sermo’s published polling methodology rules out surveys used for lead generation and questions designed to force a predetermined answer. Those distinctions matter to a company whose customers pay for credible insight as well as attention.

Medicine is personal on both sides of the screen

Kirk’s connection to the medical community extends beyond running the business. After surviving acute myeloid leukemia and receiving a blood stem cell transplant, he founded Be Your Possible in 2022. Sermo supported its Run for Research campaign; the 2024 event unlocked a $500,000 company donation for medical research.

The employer’s stated values include respect, trust, collaboration and purpose. There is a practical connection between those aspirations and the product: the company depends on professionals making time to contribute. Community benefits and research payments provide different reasons to do so. Neither can be taken for granted.

Its public Barometer studies show another use for the network. A June 2026 release, based on May fieldwork with 507 U.S. healthcare providers, reported that 48% had heard patients disclose using non-FDA-approved peptides during the previous year. That is a finding about what respondents encountered, rather than a population-wide estimate of patient use.

The lesson a reader can borrow is concrete. Give a specialist community a useful reason to return, verify the expertise that matters, and design paid work around a question someone needs answered. Sermo’s history also shows the patience and expense involved. Getting doctors into a room was the beginning. Giving them reasons to keep talking became the business.